Literature DB >> 18547129

Spotlight on bupropion in major depressive disorder.

Sohita Dhillon1, Lily P H Yang, Monique P Curran.   

Abstract

Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL/Wellbutrin XR] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion. Oral three-times-daily bupropion IR was effective and generally well tolerated in the treatment of major depressive disorder (MDD). It was as efficacious and as well tolerated as some TCAs and the SSRI fluoxetine. Moreover, it was associated with less somnolence and weight gain than some TCAs. Twice-daily bupropion SR was also efficacious and generally well tolerated in the treatment of MDD. It was as effective as and had a generally similar tolerability profile to some SSRIs, but had the advantage of less somnolence and sexual dysfunction. The efficacy of bupropion XR in terms of primary efficacy measures was established in two of six well designed placebo-controlled studies. Bupropion XR also demonstrated efficacy in terms of some secondary outcomes in five of these studies. Additionally, bupropion XR was similar, in terms of the primary efficacy outcomes, to the SSRI escitalopram in two placebo-controlled trials and to the serotonin-noradrenaline reuptake inhibitor (SNRI) venlafaxine extended release (XR) in two trials (one of which was placebo-controlled), but not in a third placebo-controlled trial where venlafaxine XR was better than bupropion XR. It was generally as well tolerated as escitalopram and venlafaxine XR, but was associated with less sexual dysfunction than escitalopram. Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547129     DOI: 10.2165/00023210-200822070-00006

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  28 in total

1.  Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.

Authors:  C C Coleman; L A Cunningham; V J Foster; S R Batey; R M Donahue; T L Houser; J A Ascher
Journal:  Ann Clin Psychiatry       Date:  1999-12       Impact factor: 1.567

Review 2.  Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.

Authors:  C E Nieuwstraten; L R Dolovich
Journal:  Ann Pharmacother       Date:  2001-12       Impact factor: 3.154

3.  Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

Authors:  G W Hogeland; S Swindells; J C McNabb; A D M Kashuba; G C Yee; C M Lindley
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

4.  Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects.

Authors:  J Odishaw; C Chen
Journal:  Pharmacotherapy       Date:  2000-12       Impact factor: 4.705

5.  Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

Authors:  R J Kavoussi; R T Segraves; A R Hughes; J A Ascher; J A Johnston
Journal:  J Clin Psychiatry       Date:  1997-12       Impact factor: 4.384

6.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Authors:  Maurizio Fava; A John Rush; Michael E Thase; Anita Clayton; Stephen M Stahl; James F Pradko; J Andrew Johnston
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

7.  Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

Authors:  James W Jefferson; A John Rush; J Craig Nelson; Susan A VanMeter; Alok Krishen; Kenneth D Hampton; Donna S Wightman; Jack G Modell
Journal:  J Clin Psychiatry       Date:  2006-06       Impact factor: 4.384

8.  Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.

Authors:  M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

9.  Double-blind comparison of bupropion and fluoxetine in depressed outpatients.

Authors:  J P Feighner; E A Gardner; J A Johnston; S R Batey; M A Khayrallah; J A Ascher; C G Lineberry
Journal:  J Clin Psychiatry       Date:  1991-08       Impact factor: 4.384

10.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

View more
  7 in total

Review 1.  Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.

Authors:  Zuowei Wang; David E Kemp; Philip K Chan; Yiru Fang; Stephen J Ganocy; Joseph R Calabrese; Keming Gao
Journal:  Int J Neuropsychopharmacol       Date:  2010-09-29       Impact factor: 5.176

Review 2.  Monoamine transporters: vulnerable and vital doorkeepers.

Authors:  Zhicheng Lin; Juan J Canales; Thröstur Björgvinsson; Morgane Thomsen; Hong Qu; Qing-Rong Liu; Gonzalo E Torres; S Barak Caine
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

3.  Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers.

Authors:  Jamie N Connarn; Stephanie Flowers; Marisa Kelly; Ruijuan Luo; Kristen M Ward; Gloria Harrington; Ila Moncion; Masoud Kamali; Melivin McInnis; Meihua R Feng; Vicki Ellingrod; Andrew Babiskin; Xinyuan Zhang; Duxin Sun
Journal:  AAPS J       Date:  2017-07-06       Impact factor: 4.009

4.  The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Authors:  Gor Sarkisyan; Amanda J Roberts; Peter B Hedlund
Journal:  Behav Brain Res       Date:  2010-01-25       Impact factor: 3.332

5.  Sad benefit in face working memory: an emotional bias of melancholic depression.

Authors:  Stefanie C Linden; Margaret C Jackson; Leena Subramanian; David Healy; David E J Linden
Journal:  J Affect Disord       Date:  2011-08-27       Impact factor: 4.839

6.  Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.

Authors:  Anita H Clayton; Ross A Baker; John J Sheehan; Zachary J Cain; Robert A Forbes; Sabrina Vogel Marler; Ronald Marcus; Robert M Berman; Michael E Thase
Journal:  BMC Res Notes       Date:  2014-07-18

7.  Visualizing Patterns of Medication Switching Among Major Depressive Patients with Various Stability and Difficulty to Treatments.

Authors:  Yu-Chun Hung; Hsi-Chung Chen; Po-Hsiu Kuo; Mong-Liang Lu; Ming-Chyi Huang; Chun-Hsin Chen; Sabrina Wang; Wei-Chung Mao; Chang-Shiann Wu; Tzu-Hua Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-16       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.